secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001104659-23-018522
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q2 FY2023 net loss $13.6M; cash $146.7M; Phase 2 DME study initiated
-----------------------------------------------------------------------------

- Net loss $13.6M for Q2 FY2023 ended Dec 31, 2022 vs $12.6M same period prior year.
- Cash and cash equivalents $146.7M as of Dec 31, 2022.
- R&D expenses $10.9M, G&A expenses $3.4M, both up on higher compensation and headcount.
- Initiated Phase 2 proof-of-concept study for RZ402 in diabetic macular edema in Dec 2022.
- Anticipates initiating global Phase 3 study for RZ358 in congenital hyperinsulinism mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/0001104659-23-018522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923018522/tm236021d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-018522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer